血必净注射液治疗ICU社区获得性重症肺炎的疗效研究

Effects of Xuebijing Injection on Severe Community-Acquired Pneumonia in ICU

摘要: 目的：探讨血必净注射液治疗ICU社区获得性重症肺炎患者的疗效。方法：回顾性连续入选2023年4月~2025年2月入住深圳市罗湖区中医院重症医学科的社区获得性重症肺炎患者。将所有入选的患者分为试验组(血必净)和对照组。试验组在社区获得性重症肺炎常规的治疗方案基础上，给予血必净50 ml，Q12H，静脉滴注，连续治疗5~7 d。对照组只进行常规治疗，不使用血必净注射液输注。主要观察指标为PSI风险评级；次要疗效指标包括：机械通气时间(h)，住ICU时间(天)，总住院时间(天)，住院费用(元)，28天病死率(%)。结果：血必净注射液联合常规治疗，可以缩短ICU社区获得性重症肺炎患者的机械通气时间，减少住ICU时间，降低住院费用，改善患者病情。结论：血必净注射液为ICU社区获得性重症肺炎患者提供了有效的治疗选择。

Abstract: Objective: To investigate the effects of Xuebijing Injection on patients with severe community-acquired pneumonia in ICU. Methods: Patients with severe community-acquired pneumonia in Intensive Care Unit of Shenzhen Luohu Hospital of Traditional Chinese Medicine from April 2023 to February 2025 were retrospectively enrolled. The patients were classfied into the Xuebijing group and the control group. Xuebijing group was given intravenous infusion of Xuebijing injection 50 mL q12h intravenuous for 5~7 days, together with the conventional treatments. While the control group only received conventional treatment and did not use Xuebijing injection infusion. The main outcome measure was PSI risk rating，whereas the secondary outcome measures included mechanical ventilation time, length of stay in ICU, hospitalization cost，and 28-day mortality. Results: Xuebijing injection combined with conventional therapy significantly shorten the period of mechanical ventilation time and length of stay in ICU, reduce the hospitalization cost, and improve the condition of the patients with severe community-acquired pneumonia. Conclusion: Xuebijing injection provides an effective treatment option for patients with severe community-acquired pneumonia in ICU.